Unknown primary carcinoma, diagnosed as inflammatory breast cancer, and successfully treated with trastuzumab and vinorelbine

被引：10

作者：

Asakura H. ^{[1
]}

Takashima H. ^{[1
]}

Mitani M. ^{[1
]}

Haba R. ^{[2
]}

Seo R. ^{[1
]}

Yokoe K. ^{[1
]}

Toyama Y. ^{[1
]}

Ohkawa M. ^{[1
]}

机构：

[1] Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, 1750-1 Ikenobe, Miki-cho

[2] Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa

来源：

International Journal of Clinical Oncology | 2005年 / 10卷 / 4期

关键词：

Inflammatory breast cancer; Trastuzumab; Unknown primary carcinoma;

D O I：

10.1007/s10147-005-0485-x

中图分类号：

学科分类号：

摘要：

Occult breast cancer presenting with axillary lymph node metastases is uncommon, and inflammatory breast cancer (IBC), as a subtype, is quite rare. Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine. Specifically, a 55-year-old woman presented with right axillary lymphadenopathy. Although she underwent various examinations, the primary site of the disease was not revealed. Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma. The patient chose to be treated by alternative medicine. About 6 months later, she was referred to our hospital, due to marked bilateral neck and axillary lymph node swelling. She presented with diffuse right breast enlargement, redness, and peau d'orange. Computed tomography (CT) of the breast showed skin thickening and swelling of the right breast.F-18 Fluorodeoxyglucose positron emission tomography (FDG-PET) showed FDG uptake in the right breast. The patient was clinically diagnosed with IBC. Because overexpression of the human epidermal growth factor receptor 2 (HER2) was found in the specimen from her right axillary lymph node, she was treated with trastuzumab and vinorelbine. Two months after the start of chemotherapy, CT revealed a complete response in the lymph nodes, and the skin thickening and parenchymal edema of the right breast had improved. FDG-PET was also performed at this time, and revealed no FDG uptake in either the right breast or the lymph nodes. © The Japan Society of Clinical Oncology 2005.

引用

页码：285 / 288

页数：3

共 19 条

[11] Aziz S.A., Pervez S., Khan S., Case control study of prognostic markers and disease outcome in inflammatory breast carcinoma: A unique clinical experience, Breast J, 7, pp. 398-404, (2001)
[12] Vogel C.L., Cobleigh M.A., Tripathy D., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, pp. 719-726, (2002)
[13] Burstein H.J., Harris L.N., Marcom P.K., Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm, J Clin Oncol, 21, pp. 2889-2895, (2003)
[14] Pegram M., Hsu S., Lewis G., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 18, pp. 2241-2251, (1999)
[15] Burstein H.J., Harris L.N., Gelman R., Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study, J Clin Oncol, 21, pp. 46-53, (2003)
[16] Baron P.L., Moore M.P., Kinne D.W., Occult breast cancer presenting with axillary metastases: Updated management, Arch Surg, 125, pp. 210-214, (1990)
[17] Slamon D.J., Godophin W., Jones L.A., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, pp. 707-712, (1989)
[18] Weiner D.B., Nordberg J., Robinson R., Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinoma of the lung, Cancer Res, 50, pp. 421-425, (1990)
[19] D'Emilia J., Bulovas K., D'Ercole K., Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon, Oncogene, 4, pp. 1233-1239, (1989)

← 1 2 →